<SEC-DOCUMENT>0001178913-25-000420.txt : 20250212
<SEC-HEADER>0001178913-25-000420.hdr.sgml : 20250212
<ACCEPTANCE-DATETIME>20250212070506
ACCESSION NUMBER:		0001178913-25-000420
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250212
FILED AS OF DATE:		20250212
DATE AS OF CHANGE:		20250212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MediWound Ltd.
		CENTRAL INDEX KEY:			0001593984
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36349
		FILM NUMBER:		25611928

	BUSINESS ADDRESS:	
		STREET 1:		42 HAYARKON STREET
		CITY:			YAVNE
		STATE:			L3
		ZIP:			8122745
		BUSINESS PHONE:		97289324010

	MAIL ADDRESS:	
		STREET 1:		42 HAYARKON STREET
		CITY:			YAVNE
		STATE:			L3
		ZIP:			8122745
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2532706.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 25.1.1.5279
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160; 20549<br>
      ______________________</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT&#160;OF FOREIGN PRIVATE ISSUER</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16 of the<br>
      Securities Exchange Act of 1934</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of February 2025</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Commission File Number: 001-36349</div>
    <div style="text-align: center; line-height: 1.25;">
      <div><br>
      </div>
      <font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>MediWound Ltd.&#160;</u></font><u> </u><br>
      (Translation of registrant&#8217;s name into English)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">42 Hayarkon Street</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Yavne, 8122745 Israel</div>
    <div style="text-align: center; line-height: 1.25;">&#160;(Address of principal executive offices)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Form 20-F &#9746;</font> &#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Form
        40-F &#9744;</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
      101(b)(1):&#160;&#160; __</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
      101(b)(7):&#160;&#160; __</div>
    <div style="line-height: 1.25">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On February 12, 2025, MediWound Ltd. (the &#8220;Company&#8221;) issued a press release entitled &#8220;MediWound Initiates the VALUE
      Global Phase III Pivotal Trial of EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for Treatment of Venous Leg Ulcers&#8221;. A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this &#8220;Form 6-K&#8221;) as Exhibit 99.1.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes of
      senior management of the Company), is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August
      9, 2022 and August 15, 2023&#160;(Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022, March 31, 2023 and August 29, 2024
      (Registration Nos. 333-265203, 333-268297 and 333-281843, respectively).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURE</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
      signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zdda80051a1eb4609a7a9d534f612e9c3">

          <tr>
            <td style="width: 50.00%;">
              <div>Date: February 12, 2025<br>
              </div>
            </td>
            <td style="width: 50%;">
              <div>&#160;&#160;&#160;&#160;&#160; MEDIWOUND LTD.</div>
              <div> <br>
              </div>
              <div>By:&#160; <u>/s/ </u><u>Hani Luxenburg</u>&#160;&#160;&#160;&#160;&#160;&#160; <br>
                </div>
              <div>Name:&#160; Hani Luxenburg </div>
              <div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Title:&#160; &#160; Chief Financial Officer</div>
                 </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">The following exhibit is filed as part of this Form 6-K:</div>
    <div style="line-height: 1.25;"><br>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top;"><u>Exhibit</u></td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Description</u></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z3a7bf0ce76924e53a4f47284e0b2cc2c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 72pt; vertical-align: top;"><a href="exhibit_99-1.htm">99.1</a></td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><a href="exhibit_99-1.htm">Press release dated February 12, 2025 entitled &#8220;MediWound
                Initiates the VALUE Global Phase III Pivotal Trial of EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for Treatment of Venous Leg Ulcers&#8221;.</a></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
  </div>
  <div style="text-align: center;" class="BRPFPageNumberArea">
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 25.1.1.5279
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> </u>
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 99.1</u><br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <img src="image00001.jpg"></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Treatment of Venous Leg Ulcers</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-style: italic;">Phase III trial to assess the efficacy and safety of EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for debridement and facilitation of active
      wound closure</div>
    <div style="line-height: 1.25; font-size: 11pt;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-style: italic;">
      <div style="line-height: 1.25; font-style: italic;">Interim analysis planned after 65% of patients complete treatment, expected in mid-2026</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 11pt; font-style: italic;">Strategic research collaborations with Solventum, M&#246;lnlycke, and MIMEDX</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">YAVNE, Israel, February 12, 2025</font> -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced
      the initiation of VALUE, a global, pivotal Phase III trial evaluating EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> for the treatment of venous leg ulcers (VLUs).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;We are proud to initiate the VALUE study, the most comprehensive VLU trial in over a decade,&#8221; said Ofer Gonen, Chief Executive Officer of MediWound. &#8220;With no new FDA-approved drugs in this category
      since 1965, EscharEx has the potential to redefine the standard of care for chronic wound debridement. EscharEx has already demonstrated its ability to effectively and rapidly debride chronic wounds in multiple Phase II trials, surpassing the current
      $375+ million market leader in wound debridement, SANTYL<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. We are confident that EscharEx will provide meaningful benefits to patients, healthcare providers, and payors alike.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The VALUE study is a global, multicenter, prospective, randomized, double-blind, placebo-controlled trial with an adaptive design, that will be conducted across 40 sites in the U.S. and Europe. Its
      primary objective is to evaluate the efficacy and safety of EscharEx in achieving effective debridement and preparing the wound bed for healing in VLUs. The study will enroll 216 patients, randomized 1:1 to receive either EscharEx or placebo.
      Patients will undergo up to eight daily applications over two weeks, followed by ten weeks of standardized wound management. Patients achieving wound bed preparation&#8212;defined as complete debridement and full coverage with granulation tissue&#8212;will
      receive a cellular/tissue-based product (CTP) or an autograft. Those achieving complete wound closure will be monitored for an additional 12 weeks.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">The study co-primary endpoints are the incidence of complete debridement and the incidence of complete wound closure. Secondary
        endpoints include the incidence of complete granulation tissue, time to debridement, time to complete wound closure, and changes in wound area. Safety and tolerability of EscharEx will be assessed throughout the trial. An interim sample size
        assessment will occur after 65% of patients complete treatments, enabling adaptive adjustments as needed. This interim analysis is expected in mid-2026.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">To support the trial, MediWound has established strategic research collaborations with Solventum, M&#246;lnlycke, and MIMEDX. These industry leaders will provide advanced products to ensure consistent
      wound management across all study sites and optimize patient outcomes.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">In addition to the VALUE study, MediWound plans to initiate a randomized, head-to-head Phase II study in 2025, comparing EscharEx to collagenase in VLU patients. This Phase II trial is designed to
      support the U.S. Biologics License Application (BLA) submission for EscharEx and strengthen MediWound&#8217;s commercialization strategy. Furthermore, the company is advancing preparations for an adaptive design Phase II/III clinical trial targeting
      diabetic foot ulcers (DFUs), which is expected to begin in 2026.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Venous Leg Ulcers<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Venous leg ulcers (VLUs) affect approximately 2% of individuals aged 65 and older, with over 1.5 million new cases reported annually in the U.S. These ulcers typically develop on the lower
      extremities due to chronic venous insufficiency. VLUs are characterized by large, shallow wounds that can cause severe pain, infection, and disability, highlighting the urgent need for effective treatment options. Debridement, a critical first step
      in managing these wounds, is performed in 68% of cases and is commonly achieved through enzymatic methods like SANTYL<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, autolytic debridement, or sharp debridement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About EscharEx</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds, currently in the advanced stages of clinical development. It is a
      concentrate of proteolytic enzymes, enriched with bromelain, designed for topical and easy-to-use daily applications. In three previous Phase II trials, EscharEx was shown to be safe and well-tolerated. It demonstrated efficacy in debridement, the
      promotion of granulation tissue, and the reduction of bioburden and biofilm in various hard-to-heal wounds, effectively preparing the wound bed for healing. EscharEx is currently being investigated in a global Phase III study for the treatment of
      venous leg ulcers (VLUs). Preparations are underway for a Phase II/III study targeting diabetic foot ulcers (DFUs).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About MediWound</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative
      biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">MediWound&#8217;s first drug, NexoBrid<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the
      need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials
      have shown EscharEx has distinct advantages over the currently available $375+ million drug for wound debridement, presenting a unique opportunity for significant market growth.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">For more information visit <u>www.mediwound.com</u> and follow us on <u>LinkedIn</u><font style="font-weight: bold;">.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">MediWound&#160;cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect,&#160;believe,&#160;or
      anticipate will or may occur in the future are forward-looking statements.&#160;Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current&#160;expectations about future events affecting
      us and are subject to risks, assumptions,&#160;uncertainties,&#160;and factors, all of which are difficult to predict and many of which are beyond our control.&#160; Actual results may differ materially from those expressed or implied by the forward-looking
      statements in this press release.&#160; These statements are often, but are not always, made through the use of words or phrases such as &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;continues,&#8221; &#8220;believe,&#8221; &#8220;guidance,&#8221; &#8220;outlook,&#8221; &#8220;target,&#8221;
      &#8220;future,&#8221; &#8220;potential,&#8221; &#8220;goals&#8221; and similar words or phrases, or future or conditional verbs such as &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; or similar expressions.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
      <hr noshade="noshade" align="left" style="text-align: left; background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
      <div style="text-align: left; line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Primary research, Alira Health analysis (2025)</div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">Specifically, this press release contains forward-looking statements concerning&#160;the anticipated progress, development, study design, expected data timing, objectives anticipated timelines,
      expectations and commercial potential of EscharEx<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of
      the product development process; the timing and conduct of our studies of EscharEx, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by
      the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of EscharEx in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings
      and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of EscharEx; our ability to maintain adequate protection of our intellectual property; competition
      risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell
      and support the use of our products and product candidates in the future.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">These and other significant factors are discussed in greater detail in MediWound&#8217;s annual report on Form 20-F for the year ended&#160;December 31, 2023, filed with the&#160;Securities and Exchange
      Commission&#160;(&#8220;SEC&#8221;) on&#160;March 21, 2024 and Quarterly Reports on Form 6-K and other filings with the&#160;SEC&#160;from time-to-time. These forward-looking statements reflect MediWound&#8217;s current views as of the date hereof and&#160;MediWound&#160;undertakes, and
      specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">MediWound Contacts:</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" border="0" id="zf0321b38996e4e73bf39046219721cd3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50.00%;">
              <div>
                <div style="text-align: justify; line-height: 1.25;">Hani Luxenburg <br>
                </div>
                <div style="text-align: justify; line-height: 1.25;">Chief Financial Officer<br>
                </div>
                <div style="text-align: justify; line-height: 1.25;">MediWound Ltd.<br>
                </div>
                <div style="line-height: 1.25;">
                  <div style="text-align: left; line-height: 1.25;"><u>ir@mediwound.com</u></div>
                </div>
              </div>
            </td>
            <td style="width: 50.00%;">
              <div>Daniel Ferry</div>
              <div>Managing Director<br>
                LifeSci Advisors, LLC<br>
                <u>daniel@lifesciadvisors.com</u></div>
              <div> </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Media Contact:&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">Ellie Hanson<br>
        FINN Partners for MediWound</div>
      <div style="line-height: 1.25;"><u>ellie.hanson@finnpartners.com</u></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf31b4275186d43479a55e77145f1957d">

        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="line-height: 1.25;">+1-929-588-2008</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !4 .,# 2(  A$! Q$!_\0
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.1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
